EIN Presswire

AVM Biotechnology President Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

Dr. Theresa Deisher

AVM Biotechnology

Dr. Theresa Deisher has been invited to provide an oral presentation in the Novel & Outstanding Discoveries Track at the 2020 ESWI Virtual Conference

“I’m honored to be able to present our data, which speaks to the importance of the work being done at the company as well as the broad and significant potential of AVM0703”.”

— Dr. Theresa Deisher

SEATTLE, WA, USA, December 2, 2020 /EINPresswire.com/ — AVM Biotechnology, a company developing a proprietary and innovative form of dexamethasone, today announced that CEO/CSO, Dr. Theresa Deisher has been selected to present during the Novel and Outstanding Discoveries Track at the European Scientific Working Group on Influenza (ESWI). The ESWI 2020 Virtual Conference will run from December 6-9, connecting worldwide experts on Influenza, RSV, and COVID-19. Registration is still open and can be accessed at https://influenzaconference.org/register/register-now.

Dr. Deisher’s presentation entitled “Acute Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for Influenza A/B-induced or COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)” will be streamed live during the conference on December 9th.

“I’m honored to be able to present our data, which speaks to the importance of the work being done at the company as well as the broad and significant potential of AVM0703”, Dr. Deisher said.

Acute suprapharmacologic dexamethasone sodium phosphate as AVM0703 mobilizes very active Natural Killer T-cells (NKT) and cytotoxic T-cells. Low doses of generic dexamethasone are currently the standard of care in COVID-19 disease and mitigate cytokine release that can trigger ARDS. The high dose of dexamethasone provided by AVM0703 is expected to provide an added benefit to these patients because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected, or autoreactive cells. Rapid elimination of infected monocytes in COVID-19 patients could reduce ICU stays and decrease long-term lung damage as well as provide long term immunity. Since this treatment is microbial strain independent, it could provide an immediate therapy for future pandemics. AVM Biotechnology is currently enrolling patients with Relapsed Refractory Non-Hodgkin’s Lymphoma at several US sites, and has received FDA approval to treat moderate to severe ARDS due to COVID-19 or Influenza, enrolling Q1 2021.

AVM0703 is a patent-pending, innovative formulation of dexamethasone. This proprietary formulation does not contain excipients such as benzyl alcohol and parabens used in generic formulations which preclude the safe use of generic versions at the acute doses required to mobilize the AVM0703 novel immune cells. AVM0703 is expected to have therapeutic effects in a variety of blood cancers, solid tumors, Type 1 Diabetes, and infectious diseases. Despite the availability of vaccines and anti-virals, influenza continues to lead to ARDS in a substantial number of patients each year. COVID-19 induced ARDS is also likely to continue to be problematic, even after vaccines are available.

AVM Biotechnology is led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and four discoveries in clinical trials. AVM’s COO, Janet R. Rea, has a proven track record working with federal regulators and successfully bringing drugs to market. The Executive Board is comprised of world leaders in the areas of respiratory illness, regulatory affairs, and vaccine development, and AVM is guided by a Global Advisory Board that includes well-respected leaders in the areas of cancer and immunology. The company has received two federal SBIR grants and holds eight worldwide patent families protecting its intellectual property. AVM is committed to transforming the future of immunotherapy while reducing the potential for undesirable treatment side effects.

Contact Jena Dalpez Director of Communications and Public Relations jdalpez@avmbiotech.com

This contains certain statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and they may be accompanied by words such as “could,” “would,” “may,” “potentially,” “suggest,” “believes,” “expects,” “should,” and similar words or expressions. These forward-looking statements reflect our current views as of the date this is published, and are subject to risks, uncertainties, assumptions, changes in circumstances, and other factors; drug development and commercialization are highly risky and early clinical results in animals or humans may not reflect the full results from later stage or larger scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance, and expectations to differ materially from those expressed or implied by these statements, including statements about: future and ongoing drug development and timing; the applications of drugs to specific diseases; the potential for ongoing preclinical or clinical trial results; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving and not limited to our ability to progress in our research and development efforts, complete clinical testing, achieve our expected results, commercialize our products, avoid infringement of patients, trademarks and other proprietary rights of third parties, protect products from competition, navigate the political environment, maintain sufficient capital and funding, avoid problems with our manufacturing processes, maintain our operations, and obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place any undue reliance on such forward-looking statements. We have no obligation to release publicly the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date these statements are made or to reflect the occurrence of unanticipated events, except as may be required by law.

Jena Dalpez
AVM Biotechnology
+1 206-906-9922
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Show More

Related Articles

Back to top button
Close